|
1
|
Bade BC and Dela Cruz CS: Lung cancer
2020: Epidemiology, etiology, and prevention. Clin Chest Med.
41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schabath MB and Cote ML: Cancer progress
and priorities: Lung cancer. Cancer Epidemiol Biomarkers Prev.
28:1563–1579. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Le X, Nilsson M, Goldman J, Reck M,
Nakagawa K, Kato T, Ares LP, Frimodt-Moller B, Wolff K,
Visseren-Grul C, et al: Dual EGFR-VEGF pathway inhibition: A
promising strategy for patients with EGFR-Mutant NSCLC. J Thorac
Oncol. 16:205–215. 2021. View Article : Google Scholar
|
|
5
|
de Sousa VML and Carvalho L: Heterogeneity
in lung cancer. Pathobiology. 85:96–107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sousa V, Espírito Santo J, Silva M, Cabral
T, Alarcão AM, Gomes A, Couceiro P and Carvalho L: EGFR/erB-1,
HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic
lesions of bronchial epithelium: An immunohistochemical and genetic
study. Virchows Arch. 458:571–581. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Thun MJ: Early landmark studies of smoking
and lung cancer. Lancet Oncol. 11:12002010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Warren GW, Alberg AJ, Kraft AS and
Cummings KM: The 2014 surgeon general's report: 'The health
consequences of smoking-50 years of progress ': A paradigm shift in
cancer care. Cancer. 120:1914–1916. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Alberg AJ, Brock MV, Ford JG, Samet JM and
Spivack SD: Epidemiology of lung cancer: Diagnosis and management
of lung cancer, 3rd ed: American college of chest physicians
evidence-based clinical practice guidelines. Chest. 143(5 Suppl):
e1S–e29S. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peto J: That the effects of smoking should
be measured in pack-years: Misconceptions 4. Br J Cancer.
107:406–407. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
IARC Working Group on the Evaluation of
Carcinogenic Risks to Humans: Tobacco smoke and involuntary
smoking. IARC Monogr Eval Carcinog Risks Hum. 83:1–1438.
2004.PubMed/NCBI
|
|
12
|
Murphy SE, Palomino A, Hecht SS and
Hoffmann D: Dose-response study of DNA and hemoglobin adduct
formation by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F344
rats. Cancer Res. 50:5446–5452. 1990.PubMed/NCBI
|
|
13
|
Jalas JR, McIntee EJ, Kenney PM, Upadhyaya
P, Peterson LA and Hecht SS: Stereospecific deuterium substitution
attenuates the tumorigenicity and metabolism of the
tobacco-specific nitrosamine
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). Dose-response
study of DNA and hemoglobin adduct formation by
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in F344 rats. Chem
Res Toxicol. 16:794–806. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hecht SS: Progress and challenges in
selected areas of tobacco carcinogenesis. Chem Res Toxicol.
21:160–171. 2008. View Article : Google Scholar
|
|
15
|
Gibbons DL, Byers LA and Kurie JM:
Smoking, p53 mutation, and lung cancer. Mol Cancer Res. 12:3–13.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Brennan P, Buffler PA, Reynolds P, Wu AH,
Wichmann HE, Agudo A, Pershagen G, Jöckel KH, Benhamou S, Greenberg
RS, et al: Secondhand smoke exposure in adulthood and risk of lung
cancer among never smokers: A pooled analysis of two large studies.
Int J Cancer. 109:125–131. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hori M, Tanaka H, Wakai K, Sasazuki S and
Katanoda K: Secondhand smoke exposure and risk of lung cancer in
Japan: A systematic review and meta-analysis of epidemiologic
studies. Jpn J Clin Oncol. 46:942–951. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heloma A, Jaakkola MS, Kähkönen E and
Reijula K: The short-term impact of national smoke-free workplace
legislation on passive smoking and tobacco use. Am J Public Health.
91:1416–1418. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Klebe S, Leigh J, Henderson DW and
Nurminen M: Asbestos, smoking and lung cancer: An update. Int J
Environ Res Public Health. 17:2582019. View Article : Google Scholar
|
|
20
|
Ngamwong Y, Tangamornsuksan W, Lohitnavy
O, Chaiyakunapruk N, Scholfield CN, Reisfeld B and Lohitnavy M:
Additive synergism between asbestos and smoking in lung cancer
risk: A systematic review and meta-analysis. PLoS One.
10:e01357982015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Villeneuve PJ, Parent MÉ, Harris SA and
Johnson KC; Canadian Cancer Registries Epidemiology Research Group:
Occupational exposure to asbestos and lung cancer in men: Evidence
from a population-based case-control study in eight Canadian
provinces. BMC Cancer. 12:5952012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Topinka JB, Loli P, Dusinská M, Hurbánková
M, Kováciková Z, Volkovová K, Kazimírová A, Barancoková M, Tatrai
E, Wolff T, et al: Mutagenesis by man-made mineral fibres in the
lung of rats. Mutat Res. 595:174–183. 2006. View Article : Google Scholar
|
|
23
|
Ketfi A, Zanoun N, Laouedj I, Gharnaout M
and Fraga S: Primary lung cancer and occupational exposure in a
North African population. Pan Afr Med J. 37:1202020.In French.
|
|
24
|
Zhang X, Jiang N, Wang L, Liu H and He R:
Chronic obstructive pulmonary disease and risk of lung cancer: A
meta-analysis of prospective cohort studies. Oncotarget.
8:78044–78056. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qu YL, Liu J, Zhang LX, Wu CM, Chu AJ, Wen
BL, Ma C, Yan XY, Zhang X, Wang DM, et al: Asthma and the risk of
lung cancer: A meta-analysis. Oncotarget. 8:11614–11620. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bozinovski S, Vlahos R, Anthony D,
McQualter J, Anderson G, Irving L and Steinfort D: COPD and
squamous cell lung cancer: Aberrant inflammation and immunity is
the common link. Br J Pharmacol. 173:635–648. 2016. View Article : Google Scholar :
|
|
27
|
Ghosh A, Boucher RC and Tarran R: Airway
hydration and COPD. Cell Mol Life Sci. 72:3637–3652. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Keikha M and Esfahani BN: The relationship
between tuberculosis and lung cancer. Adv Biomed Res. 7:582018.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brenner DR, McLaughlin JR and Hung RJ:
Previous lung diseases and lung cancer risk: A systematic review
and meta-analysis. PLoS One. 6:e174792011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang C, Zhu M, Zhou W, Du J, Xiang Y, Shu
XO, Hu Z, Zhou W, Chen K, Xu J, et al: Estimation of heritability
for nine common cancers using data from genome-wide association
studies in Chinese population. Int J Cancer. 140:329–336. 2017.
View Article : Google Scholar :
|
|
31
|
Sampson JN, Wheeler WA, Yeager M,
Panagiotou O, Wang Z, Berndt SI, Lan Q, Abnet CC, Amundadottir LT,
Figueroa JD, et al: Analysis of heritability and shared
heritability based on genome-wide association studies for thirteen
cancer types. J Natl Cancer Inst. 107:djv2792015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
McKay JD, Hung RJ, Han Y, Zong X,
Carreras-Torres R, Christiani DC, Caporaso NE, Johansson M, Xiao X,
Li Y, et al: Large-scale association analysis identifies new lung
cancer susceptibility loci and heterogeneity in genetic
susceptibility across histological subtypes. Nat Genet 4.
9:1126–1132. 2017. View Article : Google Scholar
|
|
33
|
Bossé Y and Amos CI: A decade of GWAS
results in lung cancer. Cancer Epidemiol Biomarkers Prev.
27:363–379. 2018. View Article : Google Scholar
|
|
34
|
Dai J, Lv J, Zhu M, Wang Y, Qin N, Ma H,
He YQ, Zhang R, Tan W, Fan J, et al: Identification of risk loci
and a polygenic risk score for lung cancer: A large-scale
prospective cohort study in Chinese populations. Lancet Respir Med.
7:881–891. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sobue T, Moriyama N, Kaneko M, Kusumoto M,
Kobayashi T, Tsuchiya R, Kakinuma R, Ohmatsu H, Nagai K, Nishiyama
H, et al: Screening for lung cancer with low-dose helical computed
tomography: Anti-lung cancer association project. J Clin Oncol.
20:911–920. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Toyoda Y, Nakayama T, Kusunoki Y, Iso H
and Suzuki T: Sensitivity and specificity of lung cancer screening
using chest low-dose computed tomography. Br J Cancer.
98:1602–1607. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lardinois D, Weder W, Hany TF, Kamel EM,
Korom S, Seifert B, von Schulthess GK and Steinert HC: Staging of
non-small-cell lung cancer with integrated positron-emission
tomography and computed tomography. N Engl J Med. 348:2500–2507.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guhlmann A, Storck M, Kotzerke J, Moog F,
Sunder-Plassmann L and Reske SN: Lymph node staging in non-small
cell lung cancer: Evaluation by [18F]FDG positron emission
tomography (PET). Thorax. 52:438–441. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hirsch FR, Prindiville SA, Miller YE,
Franklin WA, Dempsey EC, Murphy JR, Bunn PA Jr and Kennedy TC:
Fluorescence versus white-light bronchoscopy for detection of
preneoplastic lesions: A randomized study. J Natl Cancer Inst.
93:1385–1391. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Arroliga AC and Matthay RA: The role of
bronchoscopy in lung cancer. Clin Chest Med. 14:87–98. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Risse EK, Vooijs GP and van't Hof MA:
Relationship between the cellular composition of sputum and the
cytologic diagnosis of lung cancer. Acta Cytol. 31:170–176.
1987.PubMed/NCBI
|
|
42
|
Tsoulos N, Papadopoulou E, Metaxa-Mariatou
V, Tsaousis G, Efstathiadou C, Tounta G, Scapeti A, Bourkoula E,
Zarogoulidis P, Pentheroudakis G, et al: Tumor molecular profiling
of NSCLC patients using next generation sequencing. Oncol Rep.
38:3419–3429. 2017.PubMed/NCBI
|
|
43
|
Xie Y, Todd NW, Liu Z, Zhan M, Fang H,
Peng H, Alattar M, Deepak J, Stass SA and Jiang F: Altered miRNA
expression in sputum for diagnosis of non-small cell lung cancer.
Lung Cancer 6. 7:170–176. 2010. View Article : Google Scholar
|
|
44
|
Spira A, Beane JE, Shah V, Steiling K, Liu
G, Schembri F, Gilman S, Dumas YM, Calner P, Sebastiani P, et al:
Airway epithelial gene expression in the diagnostic evaluation of
smokers with suspect lung cancer. Nat Med. 13:361–366. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rotunno M, Hu N, Su H, Wang C, Goldstein
AM, Bergen AW, Consonni D, Pesatori AC, Bertazzi PA, Wacholder S,
et al: A gene expression signature from peripheral whole blood for
stage I lung adenocarcinoma. Cancer Prev Res (Phila). 4:1599–1608.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pennell NA, Arcila ME, Gandara DR and West
H: Biomarker testing for patients with advanced non-small cell lung
cancer: Real-world issues and tough choices. Am Soc Clin Oncol Educ
Book. 39:531–542. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Planchard D, Popat S, Kerr K, Novello S,
Smit EF, Faivre-Finn C, Mok TS, Reck M, Van Schil PE, Hellmann MD,
et al: Metastatic non-small cell lung cancer: ESMO clinical
practice guidelines for diagnosis, treatment and follow-up. Ann
Oncol. 29(Suppl 4): iv192–iv237. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wu YL, Planchard D, Lu S, Sun H, Yamamoto
N, Kim DW, Tan DSW, Yang JC, Azrif M, Mitsudomi T, et al: Pan-Asian
adapted clinical practice guidelines for the management of patients
with metastatic non-small-cell lung cancer: A CSCO-ESMO initiative
endorsed by JSMO, KSMO, MOS, SSO and TOS. Ann Oncol. 30:171–210.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Li BT, Ross DS, Aisner DL, Chaft JE, Hsu
M, Kako SL, Kris MG, Varella-Garcia M and Arcila ME: HER2
amplification and HER2 mutation are distinct molecular targets in
lung cancers. J Thorac Oncol. 11:414–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Reungwetwattana T, Liang Y, Zhu V and Ou
SI: The race to target MET exon 14 skipping alterations in
non-small cell lung cancer: The why, the how, the who, the unknown,
and the inevitable. Lung Cancer. 103:27–37. 2017. View Article : Google Scholar
|
|
51
|
Subbiah V, Velcheti V, Tuch BB, Ebata K,
Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V,
et al: Selective RET kinase inhibition for patients with
RET-altered cancers. Ann Oncol. 29:1869–1876. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cocco E, Scaltriti M and Drilon A: NTRK
fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin
Oncol. 15:731–747. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ferrer I, Zugazagoitia J, Herbertz S, John
W, Paz-Ares L and Schmid-Bindert G: KRAS-mutant non-small cell lung
cancer: From biology to therapy. Lung Cancer. 124:53–64. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Edell ES and Cortese DA: Photodynamic
therapy in the management of early superficial squamous cell
carcinoma as an alternative to surgical resection. Chest.
102:1319–1322. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hotta K, Matsuo K, Ueoka H, Kiura K,
Tabata M and Tanimoto M: Role of adjuvant chemotherapy in patients
with resected non-small-cell lung cancer: Reappraisal with a
meta-analysis of randomized controlled trials. J Clin Oncol.
22:3860–3867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
57
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Sangha R, Price J and Butts CA: Adjuvant
therapy in non-small cell lung cancer: Current and future
directions. Oncologist. 15:862–872. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Pignon JP, Tribodet H, Scagliotti GV,
Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell
R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled
analysis by the LACE collaborative group. J Clin Oncol.
26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Travis WD, Brambilla E and Riely GJ: New
pathologic classification of lung cancer: Relevance for clinical
practice and clinical trials. J Clin Oncol. 31:992–1001. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Scagliotti GV, Fossati R, Torri V, Crinò
L, Giaccone G, Silvano G, Martelli M, Clerici M, Cognetti F and
Tonato M; Adjuvant Lung Project Italy/European Organisation for
Research Treatment of Cancer-Lung Cancer Cooperative Group
Investigators: Randomized study of adjuvant chemotherapy for
completely resected stage I, II, or IIIA non-small-cell Lung
cancer. J Natl Cancer Inst. 95:1453–1461. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Winton T, Livingston R, Johnson D, Rigas
J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E,
et al: Vinorelbine plus cisplatin vs observation in resected
non-small-cell lung cancer. N Engl J Med. 352:2589–2597. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Alexander M, Kim SY and Cheng H: Update
2020: Management of non-small cell lung cancer. Lung. 198:897–907.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Nakagawa K, Garon EB, Seto T, Nishio M,
Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, et
al: Ramucirumab plus erlotinib in patients with untreated,
EGFR-mutated, advanced non-small-cell lung cancer (RELAY): A
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 20:1655–1669. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gray JE, Villegas A, Daniel D, Vicente D,
Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, Cho BC, et al:
Three-year overall survival with durvalumab after chemoradiotherapy
in stage III NSCLC-update from PACIFIC. J Thorac Oncol. 15:288–293.
2020. View Article : Google Scholar
|
|
66
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Arteaga CL: The epidermal growth factor
receptor: From mutant oncogene in nonhuman cancers to therapeutic
target in human neoplasia. J Clin Oncol. 19(Suppl 18): 32S–40S.
2001.PubMed/NCBI
|
|
68
|
Yarden Y and Sliwkowski MX: Untangling the
ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Herbst RS: Review of epidermal growth
factor receptor biology. Int J Radiat Oncol Biol Phys. 59(Suppl 2):
S21–S26. 2004. View Article : Google Scholar
|
|
70
|
Laskin JJ and Sandler AB: Epidermal growth
factor receptor inhibitors in lung cancer therapy. Semin Respir
Crit Care Med. 25(Suppl 1): S17–S27. 2004. View Article : Google Scholar
|
|
71
|
Ellis LM: Epidermal growth factor receptor
in tumor angiogenesis. Hematol Oncol Clin North Am. 18:1007–1021.
viii2004. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Salomon DS, Brandt R, Ciardiello F and
Normanno N: Epidermal growth factor-related peptides and their
receptors in human malignancies. Crit Rev Oncol Hematol.
19:183–232. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hirsch FR, Scagliotti GV, Langer CJ,
Varella-Garcia M and Franklin WA: Epidermal growth factor family of
receptors in preneoplasia and lung cancer: Perspectives for
targeted therapies. Lung Cancer. 41(Suppl 1): S29–S42. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Midha A, Dearden S and McCormack R: EGFR
mutation incidence in non-small-cell lung cancer of adenocarcinoma
histology: A systematic review and global map by ethnicity
(mutMapII). Am J Cancer Res. 5:2892–2911. 2015.PubMed/NCBI
|
|
75
|
Goldstein NI, Prewett M, Zuklys K,
Rockwell P and Mendelsohn J: Biological efficacy of a chimeric
antibody to the epidermal growth factor receptor in a human tumor
xenograft model. Clin Cancer Res. 1:1311–1318. 1995.PubMed/NCBI
|
|
76
|
Prewett M, Rothman M, Waksal H, Feldman M,
Bander NH and Hicklin DJ: Mouse-human chimeric anti-epidermal
growth factor receptor antibody C225 inhibits the growth of human
renal cell carcinoma xenografts in nude mice. Clin Cancer Res.
4:2957–2966. 1998.PubMed/NCBI
|
|
77
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Xiong HQ, Rosenberg A, LoBuglio A, Schmidt
W, Wolff RA, Deutsch J, Needle M and Abbruzzese JL: Cetuximab, a
monoclonal antibody targeting the epidermal growth factor receptor,
in combination with gemcitabine for advanced pancreatic cancer: A
multicenter phase II Trial. J Clin Oncol. 22:2610–2616. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kim ES: Cetuximab as a single agent or in
combination with chemotherapy in lung cancer. Clin Lung Cancer.
6(Suppl 2): S80–S84. 2004. View Article : Google Scholar
|
|
80
|
Carmeliet P: Angiogenesis in health and
disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ferrara N and Adamis AP: Ten years of
anti-vascular endothelial growth factor therapy. Nat Rev Drug
Discov. 15:385–403. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Karkkainen MJ, Mäkinen T and Alitalo K:
Lymphatic endothelium: A new frontier of metastasis research. Nat
Cell Biol. 4:E2–E5. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Melincovici CS, Boşca AB, Şuşman S,
Mărginean M, Mihu C, Istrate M, Moldovan IM, Roman AL and Mihu CM:
Vascular endothelial growth factor (VEGF)-key factor in normal and
pathological angiogenesis. Rom J Morphol Embryol. 59:455–467.
2018.
|
|
85
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Gille H, Kowalski J, Li B, LeCouter J,
Moffat B, Zioncheck TF, Pelletier N and Ferrara N: Analysis of
biological effects and signaling properties of Flt-1 (VEGFR-1) and
KDR (VEGFR-2). A reassessment using novel receptor-specific
vascular endothelial growth factor mutants. J Biol Chem.
276:3222–3230. 2001. View Article : Google Scholar
|
|
87
|
Muñoz-Chápuli R, Quesada AR and Angel
Medina M: Angiogenesis and signal transduction in endothelial
cells. Cell Mol Life Sci. 61:2224–2243. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Roengvoraphoj M, Tsongalis GJ, Dragnev KH
and Rigas JR: Epidermal growth factor receptor tyrosine kinase
inhibitors as initial therapy for non-small cell lung cancer: Focus
on epidermal growth factor receptor mutation testing and
mutation-positive patients. Cancer Treat Rev. 39:839–850. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Li N, Zeng A, Wang Q, Chen M, Zhu S and
Song L: Regulatory function of DNA methylation mediated lncRNAs in
gastric cancer. Cancer Cell Int. 22:2272022. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Tammela T, Enholm B, Alitalo K and
Paavonen K: The biology of vascular endothelial growth factors.
Cardiovasc Res. 65:550–563. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Ferrara N: Role of vascular endothelial
growth factor in physiologic and pathologic angiogenesis:
Therapeutic implications. Semin Oncol. 29(Suppl 6): S10–S14. 2002.
View Article : Google Scholar
|
|
92
|
Longo R, Sarmiento R, Fanelli M,
Capaccetti B, Gattuso D and Gasparini G: Anti-angiogenic therapy:
Rationale, challenges and clinical studies. Angiogenesis.
5:237–256. 2002. View Article : Google Scholar
|
|
93
|
Manzo A, Montanino A, Carillio G, Costanzo
R, Sandomenico C, Normanno N, Piccirillo MC, Daniele G, Perrone F,
Rocco G and Morabito A: Angiogenesis inhibitors in NSCLC. Int J Mol
Sci. 18:20212017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Tabernero J: The role of VEGF and EGFR
inhibition: Implications for combining anti-VEGF and anti-EGFR
agents. Mol Cancer Res. 5:203–220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Vallböhmer D, Zhang W, Gordon M, Yang DY,
Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, et
al: Molecular determinants of cetuximab efficacy. J Clin Oncol.
23:3536–3544. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Viloria-Petit A, Crombet T, Jothy S,
Hicklin D, Bohlen P, Schlaeppi JM, Rak J and Kerbel RS: Acquired
resistance to the antitumor effect of epidermal growth factor
receptor-blocking antibodies in vivo: A role for altered tumor
angiogenesis. Cancer Res. 61:5090–5101. 2001.PubMed/NCBI
|
|
97
|
Rak J, Yu JL, Kerbel RS and Coomber BL:
What do oncogenic mutations have to do with angiogenesis/vascular
dependence of tumors? Cancer Res. 62:1931–1934. 2002.PubMed/NCBI
|
|
98
|
Bergers G, Song S, Meyer-Morse N,
Bergsland E and Hanahan D: Benefits of targeting both pericytes and
endothelial cells in the tumor vasculature with kinase inhibitors.
J Clin Invest. 111:1287–1295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Viloria-Petit AM and Kerbel RS: Acquired
resistance to EGFR inhibitors: Mechanisms and prevention
strategies. Int J Radiat Oncol Biol Phys. 58:914–926. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Seto T, Kato T, Nishio M, Goto K, Atagi S,
Hosomi Y, Yamamoto N, Hida T, Maemondo M, Nakagawa K, et al:
Erlotinib alone or with bevacizumab as first-line therapy in
patients with advanced non-squamous non-small-cell lung cancer
harbouring EGFR mutations (JO25567): An open-label, randomised,
multicentre, phase 2 study. Lancet Oncol. 15:1236–1244. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Saito H, Fukuhara T, Furuya N, Watanabe K,
Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori
K, et al: Erlotinib plus bevacizumab versus erlotinib alone in
patients with EGFR-positive advanced non-squamous non-small-cell
lung cancer (NEJ026): Interim analysis of an open-label,
randomised, multicentre, phase 3 trial. Lancet Oncol. 20:625–635.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Zhang TT, Wang RM, Yang Z and Chen GB:
Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in
the treatment of advanced non-small-cell lung cancer: A
meta-analysis of randomized controlled trials. Clin Transl Oncol.
18:576–581. 2016. View Article : Google Scholar
|
|
103
|
Qi WX, Wang Q, Jiang YL, Sun YJ, Tang LN,
He AN, Min DL, Lin F, Shen Z and Yao Y: Overall survival benefits
for combining targeted therapy as second-line treatment for
advanced non-small-cell-lung cancer: A meta-analysis of published
data. PLoS One. 8:e556372013. View Article : Google Scholar : PubMed/NCBI
|
